China's generic drugs set off the next international business opportunity

Source: pharmaceutical economic news 2015-10-14 Hengrui cyclophosphamide accounts for 40% of the market share of basic leukemia drugs in the United States, and oxaliplatin for injection in hausen opens the door for EU listing Lianyungang Economic and Technological Development Zone, as the junction of land and sea in the Silk Road Economic Belt, is stepping into the internationalization of life and health industry It is also the pharmaceutical industry cluster that is leading the country by relying on its innovation capability This year, Lianyungang Development Zone is committed to building a "China Health port" One belt, one road, was also presented by Guan Yongjian, Secretary of the Lianyungang Municipal Committee and the party secretary of the Lianyungang economic and Technological Development Zone, in Lianyungang's 2015 pharmaceutical industry summit "The strategy of" one belt and one road "provides more opportunities for the internationalization of life and health industry The development zone will seize the policy opportunity, strive to build a pharmaceutical cluster with strong innovation ability, high technology content and significant agglomeration effect, and enhance the international influence of "China Health port" Decoding: in the view of sun piaoyang, chairman of Hengrui pharmaceutical, innovation and internationalization, the rise of pharmaceutical enterprises in the development zone is closely related to the two major strategies closely surrounding technological innovation and internationalization "At present, from a global perspective, the pharmaceutical industry is one of the most promising high-tech industries recognized internationally In recent years, biomedical technology in foreign countries has shown a rapid development trend, and revolutionary treatment methods continue to emerge " Sun Piaoyang said In recent years, the world's heavyweight drugs continue to appear For example, last year, Geely's hepatitis C drug, effective, reached a sales volume of 16 billion US dollars a year after its launch, which has never been seen in the entire medical history "For our pharmaceutical enterprises, only by independent innovation, providing drug use guarantee for Chinese people, accelerating drug development and having their own core technology, can we not further widen the gap with the world level in the new round of global pharmaceutical market competition." In response, Xie Bing, chairman of Zhengda pharmaceutical, also said, "Zhengda Group attaches great importance to the research and development of new products and has set up a new product research and development department Take 2014 as an example, R & D investment accounts for 8% - 9% of total sales By the first half of this year (to June 30), our total R & D expenditure exceeded 1 billion yuan, accounting for 13.7% of the company's revenue " In addition, Xie Bing believes that the rapid development of Internet has brought great changes to the traditional medicine industry Where is the way out? Or innovation "Throughout the current application of the Internet in the field of medicine in China, due to the general lack of medical knowledge of Internet users who are not born in the field of medicine, it is difficult to achieve accurate health information dissemination or disease treatment related information." "How to achieve a precise docking between the pharmaceutical industry and the Internet is the direction we are trying to achieve," Xie said Xie Bing introduced that Zhengda pharmaceutical is exploring all possible Internet applications in the fields of hospitals, doctors, patients and circulation, and adopting cooperation, merger and acquisition and other ways to shorten the time to enter the Internet field To this end, ran Yun, chairman of Guojin securities, also said: "the Internet trend is gradually affecting the medical industry, and it is possible to extend new industries and business models." Future: Shen Lingjia, deputy general manager of Hengrui pharmaceutical, the next international business opportunity, believes that in addition to the development and establishment of a relatively complete R & D system by the enterprise itself, strengthening diversified cooperation is also one of the important ways to extend the innovation ability of pharmaceutical enterprises "For example, the mode of industry university research association is to establish the industry university research association with technology innovation as the core, benefit sharing as the link and contractual relationship as the guarantee, to cooperate with professional cro companies to make up for the deficiencies of the platform Of course, it also includes the combination with domestic and foreign pharmaceutical enterprises Shen said Ran Yun, chairman of Guojin securities, also said: "we judge that in the next five years, the cooperation between the domestic pharmaceutical industry and global medical resources will be more frequent and closer, including the introduction of Chinese capital and products overseas, as well as overseas resources into China." In fact, the innovation strength and internationalization process go hand in hand The reporter learned that in recent years, Hengrui has continuously brought innovative drugs and new molecules independently developed into the European and American markets and explored new international business opportunities Shen Lingjia introduced that in 2009, Hengrui was the first DPP4 inhibitor to treat diabetes in the United States; in 2013, GPR40, also a preparation in the field of this disease, entered the U.S FDA phase I clinical; in 2015, HRE-2 inhibitors in the field of tumor treatment also entered the U.S phase I clinical "At present, Hengrui has 19 APIs and 17 preparation products which have entered the United States, Europe and Japan respectively These products have entered the high-end market for sale " Shen Lingjia further said In addition, as a generic drug, cyclophosphamide, a cancer chemotherapy drug produced by Hengrui, has occupied 40% of the U.S market share and reached 70 million US dollars in the first half of this year It is expected that the future momentum will also be strong "The global rigid growth demand and market potential are great In the past five years, there are many patents to expire, and there will be a large market space for these generic drugs," Shen said And with the continuous improvement of China's regulatory approval capacity and the strengthening of the rigid requirements for quality consistency, China's generic drugs can also quickly meet the FDA's standards " "In fact, we also see some opportunities Recently, India, a big country of generic drugs, has been warned by the FDA in terms of drug quality At the same time, due to the high cost of production in Europe and the United States, it wants to make generic drugs in areas other than its own, which brings China a good international opportunity for generic drugs " Shen Lingjia further explains.